Modulation of toll-like receptors by insulin

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages

  Tilich, Marina ^a   Arora, Rohit R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

diabetes mellitus; drug targets; inflammation; insulin resistance; ligand; obesity; toll like receptor

Indexed keywords

IMIQUIMOD; MONOCLONAL ANTIBODY; PIOGLITAZONE; PROTEIN INHIBITOR; ROSIGLITAZONE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; TROGLITAZONE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTICLE; ATHEROSCLEROSIS; BASAL CELL CARCINOMA; COLORECTAL CARCINOMA; CONDYLOMA ACUMINATUM; CUTANEOUS T CELL LYMPHOMA; EFFECTOR CELL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY CARCINOMA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERFERONS; TOLL-LIKE RECEPTORS;

EID: 80052739159     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e71fa0     Document Type: Article

References (51)

1. Wolowczuk I, Verwaerde C, Viltart O, et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol. 2008;2008:639803.
2. Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus. 2008;17:937-942.
3. Michelsen K, Doherty T, Shah P, et al. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol. 2004;173:5901-5907. (Pubitemid 39487741)
4. Devaraj S, Dasu MR, Park SH, et al. Increased levels of ligands of toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009;52:1665-1668.
5. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
6. Balistreri CR, Colonna-Romano G, Lio D, et al. TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol. 2009; 29:406-415.
7. Lee JY, Hwang DH. The modulation of inflammatory gene expression by lipids: mediation through toll-like receptors. Mol Cells. 2006;21:174-185.
8. Gearing AJ. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol. 2007;85:490-494. (Pubitemid 47367512)
9. Means TK, Luster AD. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci. 2005;1062:242-251.
10. Kim HS, Han MS, Chung KW, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity. 2007;27:321-333. (Pubitemid 47284922)
11. Sun S, Rao NL, Venable J, et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007;6:223-235.
12. Williamson RT, Lond MD. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Brit Med J. 1901;1:760-762.
13. Reid J, Macdougall AI, Andrews MM. On the efficacy of salicylate in treating diabetes mellitus. Brit Med J. 1957;2: 1071-1074.
14. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008; 93:578-583. (Pubitemid 351240834)
15. Reyna SM, Ghosh S, Tantiwong P, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes. 2008;57:2595-2602.
16. Dasu MR, Devaraj S, Zhao L, et al. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008;57:3090-3098.
17. Hyö ty H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002;45:1353-1361. (Pubitemid 35244887)
18. HaverkosHW, Battula N, Drotman DP. Enteroviruses and type 1 diabetes mellitus. Biomed Pharmacother. 2003;57: 379-385. (Pubitemid 37494713)
19. Rasschaert J, Ladrière L, Urbain M, et al. Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA+ interferon-g-induced Apoptosis in Primary Pancreatic b-Cells. J Biol Chem. 2005;280:33984-33991. (Pubitemid 41443119)
20. Wen L, Peng J,Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of toll-like receptors on pancreatic islets. J Immunol. 2004;172:3173-3180. (Pubitemid 38263708)
21. Kim F, Pham M, Luttrell I, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res. 2007;100:1589-1596. (Pubitemid 46897262)
22. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002; 347:185-192. (Pubitemid 34764822)
23. Rudofsky G Jr, Reismann P, Witte S. Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care. 2004;27:179-183. (Pubitemid 38196729)
24. Buraczynska M, Baranowicz-Gaszczyk I, Tarach J, et al. Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum Immunol. 2009;70:121-124.
25. Su H, Sun X, Ma H, et al. Acute hyperglycemia exacerbates myocardial ischemia/reperfusion injury and blunts cardioprotective effect of GIK. Am J Physiol Endocrinol Metab. 2007;293:E629-E635. (Pubitemid 47358973)
26. Lee JY, Sohn KH, Rhee SH, et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem. 2001;276:16683-16689.
27. Creely SJ, McTernan PG, Kusminski C, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740-E747. (Pubitemid 46411051)
28. Ghanim H, Mohanty P, Deopurkar R, et al. Acute modulation of toll-like receptors by insulin. Diabetes Care. 2008;31:1827-1831.
29. Leffler M, Hrach T, Stuerzl M, et al. Insulin attenuates apoptosis and exerts anti-inflammatory effects in endotoxemic human macrophages. J Surg Res. 2007;143: 398-406. (Pubitemid 350101570)
30. Cuschieri J, Bulger E, Grinsell R, et al. Insulin regulates macrophage activation through activin A. Shock. 2008;29: 285-290.
31. de Mello VD, Kolehmainen M, Pulkkinen L, et al. Downregulation of genes involved in NFkappaB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study. Diabetologia. 2008;51:2060-2067.
32. Arora R, Kawano J. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4:44-49.
33. Shah PK. Innate immune pathway links obesity to insulin resistance. Circ Res. 2007;100:1531-1533. (Pubitemid 46897253)
34. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001;86:3250-3256. (Pubitemid 32674119)
35. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008;32:638-644.
36. Davis JE, Gabler NK, Walker-Daniels J, et al. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring). 2008; 16:1248-1255. (Pubitemid 351770507)
37. Radin MS, Sinha S, Bhatt BA, et al. Inhibition or deletion of the lipopolysaccharide receptor toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia. 2008;51: 336-346.
38. Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia. 2007;50: 1267-1276. (Pubitemid 46701560)
39. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005;353:9-11. (Pubitemid 41007802)
40. Tsukumo DM, Carvalho-Filho MA, Carvalheira J, et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007; 56:1986-1998. (Pubitemid 47195825)
41. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF. Inhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 2007; 56:2957-2967. (Pubitemid 47502742)
42. Liu Y, Zhang Z,Wang L, et al. TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice. J Gastroenterol Hepatol. 2010;25:209-214.
43. Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20:257-262. (Pubitemid 351483313)
44. Daubeuf B, Mathison J, Spiller S, et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol. 2007;179:6107-6114.
45. Dasu MR, Park S, Devaraj S. Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology. 2009;150:3457-3464.
46. Appel S, Mirakaj V, Bringmann A, et al. PPAR-g agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kB pathways. Blood. 2005;106:3888-3894. (Pubitemid 41739028)
47. Marion-Letellier R, Butler M, Déchelotte P, et al. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells-potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr. 2008;87: 939-948. (Pubitemid 351549239)
48. Ghanim H, Dhindsa S, Aljada A, et al. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab. 2006;91:3553-3558. (Pubitemid 44402137)
49. Ji Y, Liu J, Wang Z, et al. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009;89:887-902.
50. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003; 107:1954-1957. (Pubitemid 36506065)
51. Takagi T, Okura H, Kobayashi Y, et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv. 2009;2:524-531.